BioLayer assays Prince of Wales
Wednesday, 10 September, 2008
BioLayer Corporation [ASX: BLS] has officially entered into a commercial agreement with the Prince of Wales Medical Research Institute.
The two organisations plan to collaborate on an assay and other diagnostic tools for use in the early detection of neurodegenerative diseases such as Parkinson's.
The companies will share IP to create the new detection tools. Under the agreement, BioLayer has the option to develop existing IP from the Prince of Wales under license.
BioLayer expects to exercise that option early next year.
BioLayer has also filed a patent application for a new approach to protecting assay processes for the early detection of neurodegenerative diseases.
Fetuses can fight infections within the womb
A fetus has a functional immune system that is well-equipped to combat infections in its...
Gene therapy reverses heart failure in large animal model
The therapy increases the amount of blood the heart can pump and dramatically improves survival,...
Meditation to reduce pain is not a placebo — it's real
Mindfulness meditation has long been speculated to work by activating processes supporting the...
